Skip to content

Study · Randomized controlled trial · n = 12 · 2002

4 results

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1 Sept 2002Cited by 105 (Europe PMC)

PMID12384827 (opens in a new tab)DOI10.1055/s-2002-34790 (opens in a new tab)PepBankPUB-12384827
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In insulin-treated type 2 diabetes, pramlintide significantly reduced postprandial glucose responses versus placebo.

    In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced glucose rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose, insulin-treated subgroup
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 microg/h · intravenous · five-hour infusionAs given in this study (human).

    Source sentences

    Summary
    During the pramlintide infusion, postprandial plasma glucose and plasma glucagon responses were significantly (p < 0.05, all) reduced following ingestion of the same meal, both in the insulin-treated and non-insulin-treated subgroups.
    2 context sentences
    Summary · context
    During the placebo infusion, plasma glucose and plasma glucagon concentrations increased substantially after the meal.
    Summary · context
    Utilizing a single-blind, placebo-controlled crossover design, 24 patients with type 2 diabetes, 12 insulin-treated and 12 non-insulin-treated, underwent a standardized mixed meal test on 2 occasions during which they received, in randomized order, a five-hour intravenous infusion of placebo or pram…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In non-insulin-treated type 2 diabetes, pramlintide significantly reduced postprandial glucose responses versus placebo.

    In plain wordsIn type 2 diabetes without insulin treatment, pramlintide reduced glucose rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose, non-insulin-treated subgroup
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 microg/h · intravenous · five-hour infusionAs given in this study (human).

    Source sentences

    Summary
    During the pramlintide infusion, postprandial plasma glucose and plasma glucagon responses were significantly (p < 0.05, all) reduced following ingestion of the same meal, both in the insulin-treated and non-insulin-treated subgroups.
    2 context sentences
    Summary · context
    During the placebo infusion, plasma glucose and plasma glucagon concentrations increased substantially after the meal.
    Summary · context
    Utilizing a single-blind, placebo-controlled crossover design, 24 patients with type 2 diabetes, 12 insulin-treated and 12 non-insulin-treated, underwent a standardized mixed meal test on 2 occasions during which they received, in randomized order, a five-hour intravenous infusion of placebo or pram…
  3. 03HumanRandomized controlled trialMechanism

    In insulin-treated type 2 diabetes, pramlintide significantly reduced postprandial glucagon responses versus placebo.

    In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced glucagon rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucagon, insulin-treated subgroup
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    100 microg/h · intravenous · five-hour infusionAs given in this study (human).

    Source sentences

    Summary
    During the pramlintide infusion, postprandial plasma glucose and plasma glucagon responses were significantly (p < 0.05, all) reduced following ingestion of the same meal, both in the insulin-treated and non-insulin-treated subgroups.
    2 context sentences
    Summary · context
    During the placebo infusion, plasma glucose and plasma glucagon concentrations increased substantially after the meal.
    Summary · context
    Utilizing a single-blind, placebo-controlled crossover design, 24 patients with type 2 diabetes, 12 insulin-treated and 12 non-insulin-treated, underwent a standardized mixed meal test on 2 occasions during which they received, in randomized order, a five-hour intravenous infusion of placebo or pram…
  4. 04HumanRandomized controlled trialMechanism

    In non-insulin-treated type 2 diabetes, pramlintide significantly reduced postprandial glucagon responses versus placebo.

    In plain wordsIn type 2 diabetes without insulin treatment, pramlintide reduced glucagon rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucagon, non-insulin-treated subgroup
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    100 microg/h · intravenous · five-hour infusionAs given in this study (human).

    Source sentences

    Summary
    During the pramlintide infusion, postprandial plasma glucose and plasma glucagon responses were significantly (p < 0.05, all) reduced following ingestion of the same meal, both in the insulin-treated and non-insulin-treated subgroups.
    2 context sentences
    Summary · context
    During the placebo infusion, plasma glucose and plasma glucagon concentrations increased substantially after the meal.
    Summary · context
    Utilizing a single-blind, placebo-controlled crossover design, 24 patients with type 2 diabetes, 12 insulin-treated and 12 non-insulin-treated, underwent a standardized mixed meal test on 2 occasions during which they received, in randomized order, a five-hour intravenous infusion of placebo or pram…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.